51 results about "Lysin" patented technology

The invention discloses a bacteriophage lyase and application thereof, and particularly relates to a bacteriophage lyase with an amino acid sequence as shown in SEQ INNO.2. The bacteriophage lyase can inhibit the growth of escherichia coli, staphylococcus and salmonella, can be used as an antibacterial substance in splitting gram-negative bacteria and can be used for preparing drugs for resisting gram-negative bacteria. The lyase can be used independently or compounded with other substances, the use concentration of antibiotics can be reduced by combining the lyase with the antibiotics, toxic and side effects (such as renal toxicity of polymyxin) of drugs are reduced, and meanwhile, generation of bacterial drug resistance is delayed. After the lyase and the chitosan are combined for use, remarkable antibacterial activity is generated, the antibacterial effect can be achieved without pre-treatment on bacteria, and the practicability is improved.

The present invention relates to antibody conjugates which are particularly suitable for targeting cells expressing PTK7, in particular tumor cells. An antibody conjugate according to the present invention has structure (1): AB-[(L6) b-{Z-L-D} x] y (1) wherein AB is an antibody capable of targeting a tumor expressing PTK7; l is a joint connecting Z to D; z is a linking group; l6 is-GlcNAc (Fuc) w-(G) j-S-(L7) w '-wherein G is a monosaccharide, j is an integer in the range of 0 to 10, S is a sugar or a sugar derivative, GlcNAc is N-acetylglucosamine, and Fuc is fucose, w is 0 or 1, w' is 0, 1 or 2, and L7 is-N (H) C (O) CH2-,-N (H) C (O) CF2-or-CH2-; d is selected from the group consisting of an anthracycline, a camptothecin, a tubulysin, an endiyne, an amanitine, a duocarmycin, a maytansinoid, an aurestatin, eribulin, a BCL-XL inhibitor, a miscanthus semiaquilaria, a KSP inhibitor, a TLR agonist, an indolo-benzodiazepine dimer or a pyrrolo-benzodiazepine dimer (PBD), and an analog or prodrug thereof; b is 0 or 1; x is 1 or 2; and y is 1, 2, 3 or 4. The invention further relates to a method for preparing said antibody conjugate of structure (1) and to the use of said antibody conjugate of structure (1).

The invention discloses a piglet intestinal health targeting probiotic engineering bacterium compound as well as preparation and application thereof. The compound is FP (at) EcN-pnirNKL, wherein a) the EcN-pnirNKL is an engineering strain which is constructed by taking escherichia coli Niss1917 (EcN) as a host and carrying a recombinant plasmid pnirBMisL-NK-Lysin, and a) the EcN-pnirNKL is an engineering strain which is constructed by taking escherichia coli Niss1917 (EcN) as a host and carrying a recombinant plasmid pnirBMisL-NK-Lysin; b) the recombinant plasmid pnirBMisL-NK-Lysin comprises an NK-Lysin gene optimized by a codon, and the NK-Lysin gene is integrated into the anaerobic inducible plasmid pnirBMisL through homologous recombination; c) the FP is a composite nano-particle which takes nano mesoporous silica (MSN) as a core and is formed by crosslinking fucoidin and rhodiola rosea polysaccharide; and d) the FP (at) EcN-pnirNKL is an oral delivery system which is formed by encapsulating the engineering bacterium EcN-pnirNKL in the FP nano particles. When the compound is applied to prevention and treatment of stress response of weaned piglets, various typical symptoms, including weight loss, colon shortening, histopathological injury and colitis disease response, of the piglets induced by dextran sodium sulfate can be remarkably relieved, and meanwhile, the integrity and functions of an intestinal barrier structure are effectively protected.

Disclosed is a biological control composition comprising a known molar amount of bacilysin, or a known and high ratio of bacilysin to fengycin, uses of said composition, a method for purifying bacilysin and a method for absolute quantification of bacilysin.

A general formula for lysins based on which the activity and functionality are further screened and 24 lysins are identified and further investigated, nine of which are characterized. These lysins exhibit potent bactericidal activity, capable of lysing multiple species of Staphylococcus, Streptococcus, and / or Enterococcus; demonstrate robust environmental resistance and stability, retaining activity under varying temperatures, NaCl concentrations, pH levels, and in immune serum; and effectively treat localized and systemic infections. These lysins and their variants are promising as antimicrobial agents for eradicating bacteria, preventing bacterial infections, or treating bacterial infections (caused by genera Staphylococcus, Streptococcus, and / or Enterococcus).

The present invention relates to a novel pharmaceutical composition comprising an effective amount of an active agent and a pharmaceutically acceptable excipient wherein the active agent is a polypeptide having killing activity against Gardnebacterium genus, and wherein the excipient is a polyacrylic acid polymer. The invention also relates to the use of the pharmaceutical composition in the treatment of Gardnebacterium infections, in particular bacterial vaginosis.

This invention relates to recombinant lyases and variants thereof, which have improved stability or bactericidal activity relative to the recombinant lyases. This application also relates to pharmaceutical compositions comprising the recombinant lyases and variants thereof, and their use for the prevention and / or treatment of bacterial infections (e.g., bacterial vaginosis).

The invention discloses gram-negative bacterium lyase and application thereof, and relates to the technical field of biological medicine. The gram-negative bacterium lyase is a lyase lysin of which the amino acid sequence is as shown in SEQ ID NO.1 or a lyase lysin-Mix of which the amino acid sequence is as shown in SEQ ID NO.3. The gram-negative bacterium lyase is a lyase lysin of which the amino acid sequence is as shown in SEQ ID NO.1. According to the invention, a novel lyase lysin is excavated from a bacteriophage, and the lyase lysin is subjected to bioinformatics analysis and modification, so that a novel lyase, namely lysin-Mix, is prepared. A lyase activity detection experiment shows that the modified new lyase can penetrate through the outer membrane of gram-negative bacteria and has good cracking activity. The invention provides technical support for developing novel antibacterial drugs.

The invention relates to the technical field of biology, in particular to a pagrosomus major antibacterial peptide Pm-NK-lysin as well as a preparation method and application of the pagrosomus major antibacterial peptide Pm-NK-lysin. The amino acid sequence of the antibacterial peptide is as shown in SEQ ID NO: 1. The minimum inhibitory concentration of the antibacterial peptide to vibrio anguillarum is not higher than 8 [mu] g / ml, and / or the minimum inhibitory concentration of the antibacterial peptide to escherichia coli is not higher than 4 [mu] g / ml. The antibacterial peptide is prepared through a pichia pastoris expression system. The antibacterial peptide is applied to preparation of an antibacterial preparation. According to the invention, efficient secretory expression of recombinant Pm-NK-lysin is successfully realized by creatively utilizing a pichia pastoris eukaryotic expression system, and a protein purification process is optimized, so that sufficient sources of high-activity recombinant protein are guaranteed. The Pm-NK-lysin provided by the invention has an excellent killing effect on aquatic pathogenic bacteria. The antibacterial peptide Pm-NK-lysin is used for replacing or reducing the use of antibiotics to control the harm of aquatic bacterial diseases, has wide popularization and application values, and certainly has far-reaching significance for promoting the green and healthy development of the aquaculture industry.

The present invention relates to compositions comprising RNA, preferably messenger RNA (mRNA), more preferably self-amplifying RNA (saRNA), and polymers, in particular cationic polymers, such as polyethylenimine (PEI), poly-L-Lysin (PEL), polyvinylamine (PVA) or polyallylamine (PAA), where individual RNA molecules are present in solution. In the formulations, the RNA is preferentially present in the form of monomers, dimers, timers or oligomers, but not as aggregates comprising a large number of RNA molecules per aggregate, in particular large polyplex nanoparticles. The formulations display improved transfection efficacy and they can be used for delivery of RNA to a subject, where they have an improved dose response relationship in comparison to formulations where large aggregates in the form of polyplex nanoparticles are present.

The application discloses a marine bacteriophage antibacterial lysin prediction method and device, medium and equipment, and relates to the fields of biological medicine and computational biology. The method comprises the following steps: constructing a training data set based on global known antibacterial protein sequences; training a protein sequence classification model based on deep learning by using the antibacterial protein data set to obtain a marine antibacterial lysin prediction model. After data standardization processing, the protein sequence of the bacteriophage to be predicted is input into the protein language model, the input sequence is subjected to self-attention modeling by a ProtT5 module, global structure and function related features are extracted, and a first feature vector is obtained; short sequence local dependency features are extracted by a ProtBERT module, and a second feature vector is obtained; the first and second feature vectors are weighted and summed to generate a fusion feature vector; and the fusion feature vector is subjected to probability prediction, and an antibacterial label and a prediction confidence of the marine bacteriophage sequence to be predicted are output.

The invention relates to the technical field of agricultural biology, in particular to an alpha spiral mutant of granulysin with improved antibacterial activity and application of the alpha spiral mutant. The amino acid sequence of the alpha spiral mutant peptide of granulysin with improved antibacterial activity is as shown in SEQ ID No: 2. According to the present invention, the antibacterial activity of the granulysin mutant on different bacteria such as gram-negative bacteria salmonella typhimurium, escherichia coli and salmonella pullorum is enhanced;

The present invention concerns antibody-conjugate having general structure (2):wherein AB is an antibody capable of targeting Trop-2-expressing tumours and D is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes such as calicheamicins, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins, pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, radioisotopes, therapeutic proteins and peptides (or fragments thereof), kinase inhibitors, MEK inhibitors, KSP inhibitors, and analogues or prodrugs thereof. These antibody-conjugates exhibit an improved therapeutic index. The invention further concerns a process for preparing the antibody-conjugate according to the invention, a method for targeting Trop-2-expressing cells, medical uses of the antibody-conjugates according to the invention.

The disclosure relates to compositions and methods of bacterial species expressing endolysins for the prophylaxis and treatment of methanogen growth in the digestive tract of an animal. More specifically, the disclosure relates to agents, compositions, and methods for preventing and / or inhibiting growth of methanogens.

The present invention relates to a live attenuated Gram-negative bacterium comprising a modified hlyCABD operon, wherein the modified hlyCABD operon is split into a first segment and a second segment, the first segment being operably linked to a first independently controlled promoter, wherein the first independently controlled promoter is a strong constitutive promoter or a strong vacuole-induced promoter, and the second segment being operably linked to a second independently controlled promoter, wherein the second independently controlled promoter is a strong vacuole-induced promoter, and wherein the first segment comprises a heterologous polynucleotide encoding a lysin upstream of a hlyAs translocation sequence, wherein the heterologous polynucleotide encoding one or more cargo molecules replaces a hlyA gene, and wherein the second segment comprises hly genes involved in secretion.

A formulation of conjugates of tubulysin analogs with a cell-binding molecule having a structure represented by Formula (I), wherein T, L, m, n, , R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 are as defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.

This invention discloses the Clostridium difficile phage recombinant lyase Lys51, its preparation method, and its application, relating to the field of genetic engineering technology. The invention involves introducing the recombinant plasmid pET-28a-SUMO-Lys51 into Escherichia coli BL21(DE3) competent cells via heat shock transformation; screening to obtain the recombinant engineered bacterium BL21(DE3)-pET-28a-SUMO-Lys51; constructing the recombinant plasmid pET-28a-SUMO-Lys51 and the recombinant engineered bacterium BL21(DE3)-pET-28a-SUMO-Lys51, further inducing the expression of Clostridium difficile phage recombinant lyase Lys51 in the recombinant engineered bacterium BL21(DE3)-pET-28a-SUMO-Lys51, and then purifying it to achieve the complete process for preparing Clostridium difficile phage recombinant lyase Lys51.

The invention relates to the technical field of agricultural biology, in particular to an antibacterial peptide chicken NK lysin mutant and application thereof. According to the present invention, the antibacterial activity of the chicken NK lysin mutant on different bacteria such as salmonella typhimurium 541, gram-negative bacteria, Escherichia coli O157: H7 1491, gram-negative bacteria, salmonella pullorum of gram-negative bacteria, and Staphylococcus aureus can be enhanced, and the antibacterial activity of the chicken NK lysin mutant on different bacteria such as salmonella typhimurium 541, gram-negative bacteria, Escherichia coli O157: H7 1491, gram-negative bacteria, salmonella pullorum of gram-negative bacteria, and Staphylococcus aureus can be enhanced;

The application discloses a recombinant bacillus Calmette-Guerin (BCG) strain and application of the recombinant BCG strain in preparation of a tumor vaccine, wherein the recombinant BCG strain comprises an HPV16 E7 antigen gene with a nucleotide sequence as shown in SEQ ID NO:1; a cytolysin ClyA gene is further fused with the HPV16 E7 to be expressed, and a rBCG-ClyA+E7 recombinant strain is constructed; the recombinant BCG strain rBCG-E7 or rBCG-ClyA+E7 is applied in preparation of a vaccine for treating cervical cancer solid tumors; the anti-tumor effect is verified in a solid tumor model through a subcutaneous injection mode; the ClyA significantly improves the expression efficiency of an exogenous antigen in the BCG, and simultaneously enhances the presentation efficiency of an antigen presenting cell; the recombinant vaccine effectively activates an anti-tumor immune response, and does not cause obvious toxic side effects, thereby providing a safe and effective candidate strategy for immunotherapy of cervical cancer and other HPV related solid tumors.

A formulation of conjugates of tubulysin analogs with a cell-binding molecule having a structure represented by Formula (I), wherein T, L, m, n, ----, R1, R2, R3, R4, R1, R6, R7, R1, R9, R10, R11, R12, and R13 are as defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.

This invention relates to the field of agricultural biotechnology, specifically to the antimicrobial peptide chicken NK lysin mutant and its applications. The chicken NK lysin mutant of this invention is effective against various bacteria, such as Salmonella typhimurium (…). Salmonella typhimurium 541, Gram-negative bacteria), Escherichia coli ( Escherichia coli O157:H7 1491, Gram-negative bacteria), Gram-negative bacteria Salmonella pullorum ( salmonella pullorum ) and Staphylococcus aureus ( Staphylococcus aureus The antibacterial activity of ) is enhanced.

This invention relates to a phage lysin LysSPYS1, a composition containing the phage lysin, and their applications. The sequence of the phage lysin LysSPYS1 is shown in SEQ ID No. 1. This phage lysin exhibits highly efficient and broad-spectrum bactericidal activity; it has a lytic effect on a variety of bacteria and can be used as a bacteriostatic agent. Furthermore, combining this phage lysin with polymyxin B can exert a synergistic antibacterial effect, significantly reducing the amount of antibiotics used. The phage lysin can also be used in combination with magnolol to achieve a prominent antibacterial effect.

The invention relates to the technical field of recombinant bacillus calmette guerin vaccines, in particular to a gene knockout attenuated granulysin / IL-12 recombinant plasmid, a recombinant bacillus calmette guerin and application. The nucleotide sequence of the recombinant plasmid is shown as SEQ ID NO: 1, and the recombinant plasmid contains IL-12 and GLS gene segments. The gene knockout attenuated granulysin / IL-12 recombinant bacillus calmette guerin vaccine contains the recombinant plasmid disclosed by the invention. The TrpD gene of the BCG is knocked out and is combined with an IL-12 / GLS double-gene eukaryotic expression system to construct a recombinant BCG strain, so that the dual functions of effect enhancement and toxicity reduction are realized, and the BCG strain is used for treating bladder cancer. The TrpD gene of the BCG is knocked out, the toxicity of the BCG is reduced, the disseminated infection risk is reduced, and the safety is improved; th1 immune imbalance is corrected, the anti-tumor effect is enhanced, tumor microenvironment Th1 type immune remodeling is induced through IL-12, and the anti-tumor effect is enhanced; a double-gene expression system is adopted, synergistic interaction is achieved, an IL-12 / GLS double-gene expression system is integrated, IL-12 regulates Th1 unbalance, and GLS directly induces tumor cell apoptosis.

The disclosure relates to compositions and methods of endolysins for the prophylaxis and treatment of bacterial infections. More specifically, the disclosure relates to agents, compositions, and methods for preventing and / or inhibiting growth of bacteria.

This invention relates to immunogenic compositions for the prevention and treatment of infection due to Streptococcus pneumoniae containing P4 peptide and / or detoxified pneumolysin protein conjugated to a T cell stimulating epitope as a contiguous peptide sequence. In particular, non-natural amino acid sequences inserted between the structures create points of conjugation that do not interfere with the generation of an effective immune response. This invention is also directed to method for the manufacture of these compositions and administration of these compositions to subjects.

The invention relates to the technical field of biology, in particular to listeria monocytogenes bacteriophage lyase Lys039 and application, and the amino acid sequence of the lyase Lys039 is shown as SEQ ID NO.1; the lyase Lys039 has the cracking activity, and shows the cracking activity on all listeria; the molecular marker has a wide splitting spectrum, but cannot split staphylococcus, bacillus subtilis and gram-negative bacteria, and has specificity. The sterilization capability is relatively high, and the concentration dependence is realized; good temperature tolerance is achieved, and the highest temperature can reach 80 DEG C; the listeria monocytogenes strain has the advantages that the listeria monocytogenes strain shows bactericidal activity in the pH range of 3-12, the listeria monocytogenes viable count can be obviously reduced in both acidic and alkaline environments, and when the pH is 6, the listeria monocytogenes strain has higher activity and shows higher acid and alkali resistance.

The present disclosure features compositions and methods for the treatment of actinomycetia (e.g., corynebacteriales) infections, e.g., caused by mycobacterial cells. In one aspect, the disclosure features a composition containing unencapsulated proteins that include one or more of (a) a Lysin A; (b) a Lysin B; (c) an isoamylase; and (d) an α-amylase. The composition optionally further includes a supramolecular structure including one or more (a) a Lysin A; (b) a Lysin B; (c) an isoamylase; and (d) an α-amylase. In another aspect, the invention features a method of treating a bacterial infection in a subject by administering a composition of unencapsulated lytic proteins as described herein to the subject in an amount and for a duration sufficient to treat the bacterial infection, optionally in combination with encapsulated lytic proteins. The encapsulated lytic proteins and the unencapsulated lytic proteins can be in the same or different composition and can be administered simultaneously or sequentially.

To provide a prostate-specific membrane antigen (PSMA) ligand.SOLUTION: The present disclosure provides a PSMA ligand having a glutamic acid-urea-lysin (GUL) part, and a chelate agent capable of including radioactive metal. The present disclosure also provides use of a compound in diagnostic imaging and a compound in medical treatments for prostate cancer.SELECTED DRAWING: None

Novel recombinant lysins and their use in the treatment of Gram-negative bacterial infections. The present invention relates to novel recombinant lysins and their use as antimicrobial agents in novel therapeutic approaches to eliminate antibiotic-resistant Gram-negative bacteria and minimize the emergence of new resistance. The present invention further relates to polynucleotides encoding the recombinant lysins of the invention, vectors and host cells comprising same, and related methods, medical uses, compositions and kits.

The present invention concerns antibody-conjugates which are especially suitable for the targeting of PTK7-expressing cells, in particular tumour cells. The antibody-conjugates according to the invention have structure (1):AB-[(L6)b-{Z-L-D}x]y  1Herein, AB is an antibody capable of targeting PTK7-expressing tumours; L is a linker that links Z to D; Z is a connecting group; L6 is -GlcNAc(Fuc)w-(G)j-S-(L7)w′-, wherein G is a monosaccharide, j is an integer in the range of 0-10, S is a sugar or a sugar derivative, GlcNAc is N-acetylglucosamine and Fuc is fucose, w is 0 or 1, w′ is 0, 1 or 2 and L7 is —N(H)C(O)CH2—, —N(H)C(O)CF2— or —CH2—; D is selected from the group consisting of anthracyclines, camptothecins, tubulysins, enediynes, amanitins, duocarmycins, maytansinoids, auristatins, eribulins, BCL-XL inhibitors, hemiasterlins, KSP inhibitors, TLR agonists, indolinobenzodiazepine dimers or pyrrolobenzodiazepine dimers (PBDs), and analogues or prodrugs thereof; b is 0 or 1; x is 1 or 2; and y is 1, 2, 3 or 4. The invention further concerns a method for preparing the antibody-conjugates of structure (1) and application of the antibody-conjugates of structure (1).